Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Opdivo Tops Japan Drug Ranking for 14 Months Running: Encise
March 8, 2023
- Japan Ethical Drug Sales Grow 3.5% in January: Crecon
March 8, 2023
- Teva Takeda Prepping for Listing of Allermist AG in June
March 8, 2023
- Kyorin Out-Licenses Vibegron to Sumitomo in 5 Asian Markets
March 7, 2023
- Azilva, Abraxane, and More Major Meds Get Add-On PMPs under Ad-Hoc Rule in FY2023: Poll
March 7, 2023
- Drug Makers Wary of Rush Demand Tied to Unprofitability Re-Pricing, Some Curb Orders
March 7, 2023
- Teijin Grants Global Rights for Kidney Disease Med to Novartis
March 7, 2023
- FDA Accepts Eisai’s Lecanemab Application for Early July Target
March 6, 2023
- Generic Makers See Milder Cuts in FY2023 Revision, Nipro to Get 1%-Plus Net Hike: Jiho Poll
March 6, 2023
- 2023 Price Cut for Top-Tier, 2nd-Tier Firms at 1-4%, Tsumura Only Original Drug Maker to See Net Rise: Jiho Poll
March 6, 2023
- Sumitomo Pharma Drops Cancer Drug Candidate Dubermatinib
March 6, 2023
- Alfresa Pharma Gets Japan Rights to Keio Biotech’s ALS Drug
March 3, 2023
- Biogen Japan, Eisai to End MS Copromotion Pact in Japan
March 3, 2023
- Neil MacGregor Takes Over as President of Amgen Japan
March 2, 2023
- Nichi-Iko to Discontinue 221 Additional Products, Generic Peers Looking into Impact
March 2, 2023
- Eylea 8 mg Filed in Japan to Extend Dosing Intervals: Bayer
March 2, 2023
- Nichi-Iko Exits North American Market, Biosimilar Biz with Sagent Sell-Off
March 1, 2023
- AstraZeneca Files Anti-RSV Antibody Nirsevimab in Japan
March 1, 2023
- Nippon Chemiphar Out-Licenses XOR Inhibitor to Chinese Pharma
March 1, 2023
- UCB Japan Files Rozanolixizumab for Generalized Myasthenia Gravis
March 1, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…